TY - JOUR
T1 - Treatment adherence in multiple sclerosis
T2 - Association with emotional status, personality, and cognition
AU - Bruce, Jared M.
AU - Hancock, Laura M.
AU - Arnett, Peter
AU - Lynch, Sharon
N1 - Funding Information:
Funding This study was funded in part by pilot grant PP1506 from the National Multiple Sclerosis Society.
PY - 2010/6
Y1 - 2010/6
N2 - The purpose of the present study was to prospectively examine the association between treatment adherence and common neuropsychiatric symptoms in multiple sclerosis (MS). Patients underwent a thorough psychiatric and neuropsychological evaluation at the outset of the study. Patient adherence to disease modifying therapies was then tracked for 8 weeks using self-report, a medication diary, and an electronic monitoring device that recorded needle disposals. Results indicated that MS patients with current mood or anxiety disorders were almost five times as likely as MS patients with no psychiatric diagnosis to exhibit problems adhering to their disease modifying therapies. Poor adherence was also associated with memory difficulties, anxiety, depression, neuroticism, and low conscientiousness. Findings highlight the importance of conducting a thorough psychiatric and neuropsychological evaluation when clinicians suspect poor adherence to disease modifying therapies. Pharmacological or psychotherapeutic treatment of mood/anxiety disorders, use of scheduled reminders, and/or increased organization and structure may lead to improved treatment adherence in MS.
AB - The purpose of the present study was to prospectively examine the association between treatment adherence and common neuropsychiatric symptoms in multiple sclerosis (MS). Patients underwent a thorough psychiatric and neuropsychological evaluation at the outset of the study. Patient adherence to disease modifying therapies was then tracked for 8 weeks using self-report, a medication diary, and an electronic monitoring device that recorded needle disposals. Results indicated that MS patients with current mood or anxiety disorders were almost five times as likely as MS patients with no psychiatric diagnosis to exhibit problems adhering to their disease modifying therapies. Poor adherence was also associated with memory difficulties, anxiety, depression, neuroticism, and low conscientiousness. Findings highlight the importance of conducting a thorough psychiatric and neuropsychological evaluation when clinicians suspect poor adherence to disease modifying therapies. Pharmacological or psychotherapeutic treatment of mood/anxiety disorders, use of scheduled reminders, and/or increased organization and structure may lead to improved treatment adherence in MS.
UR - http://www.scopus.com/inward/record.url?scp=77955970942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955970942&partnerID=8YFLogxK
U2 - 10.1007/s10865-010-9247-y
DO - 10.1007/s10865-010-9247-y
M3 - Article
C2 - 20127401
AN - SCOPUS:77955970942
SN - 0160-7715
VL - 33
SP - 219
EP - 227
JO - Journal of Behavioral Medicine
JF - Journal of Behavioral Medicine
IS - 3
ER -